This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Julander, J. G.
Right arrow Articles by Sidwell, R. W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Julander, J. G.
Right arrow Articles by Sidwell, R. W.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, June 2007, p. 1962-1966, Vol. 51, No. 6
0066-4804/07/$08.00+0     doi:10.1128/AAC.01494-06
Copyright © 2007, American Society for Microbiology. All Rights Reserved.

Activity of T-1106 in a Hamster Model of Yellow Fever Virus Infection{triangledown}

Justin G. Julander,1* Yousuke Furuta,2 Kristiina Shafer,1 and Robert W. Sidwell1

Institute for Antiviral Research, Utah State University, 5600 Old Main Hill, Logan, Utah 84322-5600,1 Toyama Chemical Company, Ltd., 3-2-5 Nishishinjuku, Shinjuku-ku, Tokyo 187-0023, Japan2

Received 28 November 2006/ Returned for modification 22 January 2007/ Accepted 28 March 2007

Yellow fever virus (YFV) causes 30,000 deaths worldwide, despite the availability of a vaccine. There are no approved antiviral therapies for the treatment of YFV disease in humans, and, therefore, these studies were designed to investigate the anti-YFV properties of T-1106, a substituted pyrazine, in a hamster model of YFV disease. Intraperitoneal (i.p.) treatment with 100 mg/kg of body weight/day of T-1106 starting 4 h prior to virus inoculation and continuing twice daily through 7 days post-virus inoculation (dpi) resulted in significantly improved survival, alanine aminotransferase levels in the serum, weight gain, and mean day to death. Virus titer in the liver at 4 dpi was significantly reduced in treated animals, as determined by both quantitative real-time PCR and infectious cell culture assay. No toxicity (weight loss or mortality) was observed at a dose of 100 mg/kg/day in sham-infected control animals. The observed minimal effective dose of T-1106 was 32 mg/kg/day administered either by oral or i.p. treatment. Therapeutic treatment was effective in significantly improving survival when T-1106 was administered beginning as late as 4 days after virus challenge with twice-daily treatment for 8 days at a dose of 100 mg/kg/day. With favorable safety, bioavailability, and postviral challenge treatment efficacy, T-1106 was effective in the treatment of disease in hamsters infected with YFV and should be further studied for potential use as a therapy for human YFV disease.

* Corresponding author. Mailing address: Institute for Antiviral Research, Utah State University, 5600 Old Main Hill, Logan, UT 84322-5600. Phone: (435) 797-7215. Fax: (435) 797-3959. E-mail: jgjulander{at}cc.usu.edu

{triangledown} Published ahead of print on 9 April 2007.

Antimicrobial Agents and Chemotherapy, June 2007, p. 1962-1966, Vol. 51, No. 6
0066-4804/07/$08.00+0     doi:10.1128/AAC.01494-06
Copyright © 2007, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Julander, J. G., Shafer, K., Smee, D. F., Morrey, J. D., Furuta, Y. (2009). Activity of T-705 in a Hamster Model of Yellow Fever Virus Infection in Comparison with That of a Chemically Related Compound, T-1106. Antimicrob. Agents Chemother. 53: 202-209 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»